Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
NCT04216472 · M.D. Anderson Cancer Center · PHASE2 · terminated · last registry update 2026-07-07 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “\<75% participation” | Open Targets' class: insufficient enrollment, negative | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PIK3CA in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-09-10Also stopped (terminated): Novartis Pharmaceuticals, alpelisib + placebo (NCT04251533)
- 2026-07-10Results posted on the registry: Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-07-10Also stopped (terminated): Novartis Pharmaceuticals, Ribociclib + Letrozole (NCT03439046)
- 2026-06-25Results posted on the registry: Novartis Pharmaceuticals, Alpelisib + Fulvestrant (NCT05631795)
- 2026-04-21Also stopped (terminated): Institut Paoli-Calmettes, BKM120 + lapatinib (NCT01589861)
- 2026-01-22Results posted on the registry: Jennifer Lee Caswell-Jin, Alpelisib + Tamoxifen (NCT05101564)
- 2025-11-24Results posted on the registry: Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-11-24Also stopped (terminated): Sanofi, Amcenestrant + Palbociclib (NCT03284957)
- 2025-10-01Also stopped (terminated): National Cancer Institute (NCI), Copanlisib + Pertuzumab (NCT04108858)
- 2025-07-28Results posted on the registry: National Cancer Institute (NCI), Copanlisib Hydrochloride + Eribulin Mesylate (NCT04345913)
- 2025-07-22Also stopped (terminated): Cancer Trials Ireland, Copanlisib + Trastuzumab emtansine (NCT04042051)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision